Health News

Viral Genetics, Inc. (Pinksheets: VRAL) continues to make the transition to a clinical-stage company. The Company’s two lead pharmaceutical programs — APi1177 for HIV/AIDS, and various Metabolic Disruption (MDT) compounds for drug-resistant cancers — are being advanced towards clinical development under sponsor- or investigator-initiated Investigational New Drug (IND) pathways…

Read more

Filed under: Pharmacy News
Tags: cancer, Drug, Genetic, Pharmacy

Related posts

• Viral Genetics cautions investors and the public to rely only on its press releases and disclosures (0)
  Viral Genetics (Pink Sheets: VRAL), a biotechnology company that develops drug compounds for HIV/AIDS, autoimmune diseases, and cancer, is issuing this announcement in response to a series of press releases distributed by collegestock.com on August 25 and August 26, and an article published on Today's Financial News entitled "TFN Reader Grapevine: There's Something About Viral [...]
  
  
• Study pinpoints compounds that repress cancer gene’s activity (0)
  A research team pursuing one of the most commonly altered genes in cancer has laid a critical foundation for understanding this gene that could point the way toward developing drugs against it. A recent study of cancer genetics pointed to the gene MCL1, which encodes a protein that helps keep cells alive Read more [tags] Pharmacy News [...]
  
  
• Study finds Olaparib can reduce tumor size in ovarian cancer women (0)
  Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations. Read [...]
  
  
• Seattle Genetics, Agensys present ASG-5ME ADC preclinical data at 101st AACR (0)
  Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today reported preclinical data with ASG-5ME, an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors. In models of human prostate and pancreatic cancer, ASG-5ME was found to have potent and long lasting antitumor activity. [...]
  
  
• Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer (0)
  Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors. Read more [tags] Pharmacy News [...]